Premium
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Author(s) -
Pratico Domenico,
Lee Virginia M.-Y.,
Trojanowski John Q.,
Rokach Joshua,
Fitzgerald Garret A.
Publication year - 1998
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.12.15.1777
Subject(s) - isoprostanes , oxidative stress , isoprostane , lipid peroxidation , arachidonic acid , pathogenesis , in vivo , medicine , endocrinology , disease , chemistry , biochemistry , biology , microbiology and biotechnology , enzyme
Alzheimer's disease (AD) includes a group of dementing neurodegenerative disorders that have diverse etiologies but the same hallmark brain lesions. Since oxidative stress may play a role in the pathogenesis of AD and isoprostanes are chemically stable peroxidation products of arachidonic acid, we measured both iPF 2α ‐III and iPF 2α ‐VI using gas chromatography‐mass spectrometry in AD and control brains. The levels of both isoprostanes, but not of 6‐keto PGF 1α , an index of prostaglandin production, were markedly elevated in both frontal and temporal poles of AD brains compared to the corresponding cerebella. Levels were also elevated compared to corresponding areas of brains from patients who had died with schizophrenia or Parkinson's disease or from nonneuropsychiatric disorders. iPF 2α ‐ IV, but not iPF 2α ‐III, levels were higher in ventricular CSF of AD brains relative to the non‐AD brains. These data suggest that specific isoprostane analysis may reflect increased oxidative stress in AD.—Praticò, D., Lee, V. M.‐Y., Trojanowski, J. Q., Rokach, J., FitzGerald, G. A. Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo . FASEB J. 12, 1777–1783 (1998)